Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress of the European Association of Nuclear Medicine.
Visit us at booth #59!
- Interesting? Share this article
Other news
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
18F-FDOPA now available
Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...
First liver cancer patient treated with microspheres irradiated in TU Delft
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Interested in a collaboration?
Contact us to discuss the possibilities.